Resveratrol-like Compounds as SIRT1 Activators
Abstract
:1. Introduction
2. Results
2.1. In-House Chemical Library of Resveratrol Derivatives
2.2. In Silico Chemical Library Screening
2.3. In Vitro SIRT1 Activity
2.4. Preventive Effects of Resveratrol and Compound 3d on Cell Viability in H2O2-Challenged HUVECs
2.5. Potential Role of Sirtuins in the Preventive Effects of Resveratrol and Compound 3d on Cell Viability in HUVECs Exposed to H2O2
2.6. Preventive Effects of Resveratrol and Compound 3d against H2O2-Induced Intracellular ROS Production
2.7. Potential Role of Sirtuins in the Preventive Effects of Resveratrol and Compound 3d against H2O2-Induced Intracellular ROS Production
3. Discussion
4. Materials and Methods
4.1. Chemistry
4.1.1. General Procedure for the Synthesis of Hydroxymethylphenols 13–15
4.1.2. 2-(Hydroxymethyl)phenol, 13
4.1.3. 3-(Hydroxymethyl)phenol, 14
4.1.4. 4-(Hydroxymethyl)phenol, 15
4.1.5. General Procedure for the Synthesis of 2-Hydroxybenzyl-oxy-isoindolin-1,3-dione 16–18
4.1.6. 2-((2-Hydroxybenzyl)-oxy)-isoindolin-1,3-dione, 16
4.1.7. 3-((2-Hydroxybenzyl)-oxy)-isoindolin-1,3-dione, 17
4.1.8. 4-((2-Hydroxybenzyl)-oxy)-isoindolin-1,3-dione, 18
4.1.9. General Procedure for the Synthesis of Aminooxymethyl-Phenols Hydrochlorides 19–21
4.1.10. 2-((Aminooxy) methyl)-phenol hydrochloride, 19
4.1.11. 3-((Aminooxy) methyl)-phenol hydrochloride, 20
4.1.12. 4-((Aminooxy) methyl)-phenol hydrochloride, 21
4.1.13. General Procedure for the Synthesis of (E)-mono and Polyhydroxy Substituted benzaldehyde O-(Benzyl) oximes 1a–e, 2a–e, 3b, 3d–e
4.1.14. (E)-2-Hydroxy-benzaldehyde-O-(2-hydroxybenzyl)-oxime 1a
4.1.15. (E)-3-Hydroxy-benzaldehyde-O-(2-hydroxybenzyl)-oxime 1b
4.1.16. (E)-4-Hydroxy-benzaldehyde-O-(2-hydroxybenzyl)-oxime 1c
4.1.17. (E)-3,5-Dihydroxy-benzaldehyde-O-(2-hydroxybenzyl)-oxime 1d
4.1.18. (E)-2,4-Dihydroxy-benzaldehyde-O-(2-hydroxybenzyl)-oxime 1e
4.1.19. (E)-2-Hydroxy-benzaldehyde-O-(3-hydroxybenzyl)-oxime 2a
4.1.20. (E)-3-Hydroxy-benzaldehyde-O-(3-hydroxybenzyl)-oxime 2b
4.1.21. (E)-4-Hydroxy-benzaldehyde-O-(3-hydroxybenzyl)-oxime 2c
4.1.22. (E)-3,5-Dihydroxy-benzaldehyde-O-(3-hydroxybenzyl)-oxime 2d
4.1.23. (E)-2,4-Didroxy-benzaldehyde-O-(3-hydroxybenzyl)-oxime 2e
4.1.24. (E)-3-Hydroxy-benzaldehyde-O-(4-hydroxybenzyl)-oxime 3b
4.1.25. (E)-3,5-Dihydroxy-benzaldehyde-O-(4-hydroxybenzyl)-oxime 3d
4.1.26. (E)-2,4-Dihydroxy-benzaldehyde-O-(4-hydroxybenzyl)-oxime 3e
4.2. Computational Details
4.2.1. Database and Protein Preparation
4.2.2. Docking Studies
4.2.3. Evaluation of Drug-like Profile
4.3. Cell-Free Assay on Isolated SIRT1 Enzyme
4.4. Cell Cultures
4.5. Cell Viability Assay
4.6. Measurement of Intracellular ROS Production
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Guzik, T.J.; Touyz, R.M. Oxidative Stress, Inflammation, and Vascular Aging in Hypertension. Hypertension 2017, 70, 660–667. [Google Scholar] [CrossRef]
- Pitocco, D.; Tesauro, M.; Alessandro, R.; Ghirlanda, G.; Cardillo, C. Oxidative Stress in Diabetes: Implications for Vascular and Other Complications. Int. J. Mol. Sci. 2013, 14, 21525–21550. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sena, C.M.; Leandro, A.; Azul, L.; Seiça, R.; Perry, G. Vascular Oxidative Stress: Impact and Therapeutic Approaches. Front. Physiol. 2018, 9, 1668. [Google Scholar] [CrossRef] [Green Version]
- Martelli, A.; Citi, V.; Calderone, V. Recent Efforts in Drug Discovery on Vascular Inflammation and Consequent Atherosclerosis. Expert Opin. Drug Discov. 2021, 16, 411–427. [Google Scholar] [CrossRef] [PubMed]
- Steven, S.; Frenis, K.; Oelze, M.; Kalinovic, S.; Kuntic, M.; Bayo Jimenez, M.T.; Vujacic-Mirski, K.; Helmstädter, J.; Kröller-Schön, S.; Münzel, T.; et al. Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. Oxidative Med. Cell. Longev. 2019, 2019, e7092151. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wadley, A.J.; Veldhuijzen van Zanten, J.J.C.S.; Aldred, S. The Interactions of Oxidative Stress and Inflammation with Vascular Dysfunction in Ageing: The Vascular Health Triad. AGE 2013, 35, 705–718. [Google Scholar] [CrossRef]
- Welsh, P.; Grassia, G.; Botha, S.; Sattar, N.; Maffia, P. Targeting Inflammation to Reduce Cardiovascular Disease Risk: A Realistic Clinical Prospect? Br. J. Pharmacol. 2017, 174, 3898–3913. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, W.; Jia, Z.; Pan, M.-H.; Anandh Babu, P.V. Natural Products for the Prevention of Oxidative Stress-Related Diseases: Mechanisms and Strategies. Oxidative Med. Cell. Longev. 2016, 2016, e4628502. [Google Scholar] [CrossRef] [PubMed]
- Martelli, A.; Piragine, E.; Gorica, E.; Citi, V.; Testai, L.; Pagnotta, E.; Lazzeri, L.; Pecchioni, N.; Ciccone, V.; Montanaro, R.; et al. The H2S-Donor Erucin Exhibits Protective Effects against Vascular Inflammation in Human Endothelial and Smooth Muscle Cells. Antioxidants 2021, 10, 961. [Google Scholar] [CrossRef]
- Saponara, S.; Testai, L.; Iozzi, D.; Martinotti, E.; Martelli, A.; Chericoni, S.; Sgaragli, G.; Fusi, F.; Calderone, V. (+/−)-Naringenin as Large Conductance Ca2+-Activated K+ (BKCa) Channel Opener in Vascular Smooth Muscle Cells. Br. J. Pharmacol. 2006, 149, 1013–1021. [Google Scholar] [CrossRef] [PubMed]
- Pengnet, S.; Prommaouan, S.; Sumarithum, P.; Malakul, W. Naringin Reverses High-Cholesterol Diet-Induced Vascular Dysfunction and Oxidative Stress in Rats via Regulating LOX-1 and NADPH Oxidase Subunit Expression. BioMed Res. Int. 2019, 2019, e3708497. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Testai, L.; Piragine, E.; Piano, I.; Flori, L.; Da Pozzo, E.; Miragliotta, V.; Pirone, A.; Citi, V.; Di Cesare Mannelli, L.; Brogi, S.; et al. The Citrus Flavonoid Naringenin Protects the Myocardium from Ageing-Dependent Dysfunction: Potential Role of SIRT1. Oxidative Med. Cell. Longev. 2020, 2020, e4650207. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chtourou, Y.; Slima, A.B.; Makni, M.; Gdoura, R.; Fetoui, H. Naringenin Protects Cardiac Hypercholesterolemia-Induced Oxidative Stress and Subsequent Necroptosis in Rats. Pharmacol. Rep. 2015, 67, 1090–1097. [Google Scholar] [CrossRef] [PubMed]
- Piano, I.; Di Paolo, M.; Corsi, F.; Piragine, E.; Bisti, S.; Gargini, C.; Di Marco, S. Retinal Neurodegeneration: Correlation between Nutraceutical Treatment and Animal Model. Nutrients 2021, 13, 770. [Google Scholar] [CrossRef] [PubMed]
- Leo, M.D.; Piragine, E.; Pirone, A.; Braca, A.; Pistelli, L.; Calderone, V.; Miragliotta, V.; Testai, L. Protective Effects of Bergamot (Citrus Bergamia Risso & Poiteau) Juice in Rats Fed with High-Fat Diet. Planta Med. 2020, 86, 180–189. [Google Scholar] [CrossRef] [PubMed]
- Da Pozzo, E.; De Leo, M.; Faraone, I.; Milella, L.; Cavallini, C.; Piragine, E.; Testai, L.; Calderone, V.; Pistelli, L.; Braca, A.; et al. Antioxidant and Antisenescence Effects of Bergamot Juice. Oxidative Med. Cell. Longev. 2018, 2018, e9395804. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Constans, J.; Bennetau-Pelissero, C.; Martin, J.-F.; Rock, E.; Mazur, A.; Bedel, A.; Morand, C.; Bérard, A.M. Marked Antioxidant Effect of Orange Juice Intake and Its Phytomicronutrients in a Preliminary Randomized Cross-over Trial on Mild Hypercholesterolemic Men. Clin. Nutr. 2015, 34, 1093–1100. [Google Scholar] [CrossRef] [PubMed]
- Howells, L.M.; Berry, D.P.; Elliott, P.J.; Jacobson, E.W.; Hoffmann, E.; Hegarty, B.; Brown, K.; Steward, W.P.; Gescher, A.J. Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases—Safety, Pharmacokinetics, and Pharmacodynamics. Cancer Prev. Res. 2011, 4, 1419–1425. [Google Scholar] [CrossRef] [Green Version]
- Brockmueller, A.; Sameri, S.; Liskova, A.; Zhai, K.; Varghese, E.; Samuel, S.M.; Büsselberg, D.; Kubatka, P.; Shakibaei, M. Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism. Cancers 2021, 13, 188. [Google Scholar] [CrossRef]
- García-Martínez, B.I.; Ruiz-Ramos, M.; Pedraza-Chaverri, J.; Santiago-Osorio, E.; Mendoza-Núñez, V.M. Influence of Age and Dose on the Effect of Resveratrol for Glycemic Control in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. Molecules 2022, 27, 5232. [Google Scholar] [CrossRef]
- Mansour, A.; Samadi, M.; Sanginabadi, M.; Gerami, H.; Karimi, S.; Hosseini, S.; Shirzad, N.; Hekmatdoost, A.; Mahdavi-Gorabi, A.; Mohajeri-Tehrani, M.R.; et al. Effect of Resveratrol on Menstrual Cyclicity, Hyperandrogenism and Metabolic Profile in Women with PCOS. Clin. Nutr. 2021, 40, 4106–4112. [Google Scholar] [CrossRef] [PubMed]
- Calderone, V.; Martelli, A.; Testai, L.; Martinotti, E.; Breschi, M.C. Functional Contribution of the Endothelial Component to the Vasorelaxing Effect of Resveratrol and NS 1619, Activators of the Large-Conductance Calcium-Activated Potassium Channels. Naunyn-Schmied Arch. Pharm. 2007, 375, 73–80. [Google Scholar] [CrossRef] [PubMed]
- Bertini, S.; Calderone, V.; Carboni, I.; Maffei, R.; Martelli, A.; Martinelli, A.; Minutolo, F.; Rajabi, M.; Testai, L.; Tuccinardi, T.; et al. Synthesis of Heterocycle-Based Analogs of Resveratrol and Their Antitumor and Vasorelaxing Properties. Bioorg. Med. Chem. 2010, 18, 6715–6724. [Google Scholar] [CrossRef]
- Ungvari, Z.; Bagi, Z.; Feher, A.; Recchia, F.A.; Sonntag, W.E.; Pearson, K.; de Cabo, R.; Csiszar, A. Resveratrol Confers Endothelial Protection via Activation of the Antioxidant Transcription Factor Nrf2. Am. J. Physiol. Heart Circ. Physiol. 2010, 299, H18–H24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xia, N.; Daiber, A.; Förstermann, U.; Li, H. Antioxidant Effects of Resveratrol in the Cardiovascular System. Br. J. Pharmacol. 2017, 174, 1633–1646. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seyyedebrahimi, S.; Khodabandehloo, H.; Nasli Esfahani, E.; Meshkani, R. The Effects of Resveratrol on Markers of Oxidative Stress in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Acta Diabetol. 2018, 55, 341–353. [Google Scholar] [CrossRef] [PubMed]
- Vilar-Pereira, G.; Carneiro, V.C.; Mata-Santos, H.; Vicentino, A.R.R.; Ramos, I.P.; Giarola, N.L.L.; Feijó, D.F.; Meyer-Fernandes, J.R.; Paula-Neto, H.A.; Medei, E.; et al. Resveratrol Reverses Functional Chagas Heart Disease in Mice. PLOS Pathog. 2016, 12, e1005947. [Google Scholar] [CrossRef] [Green Version]
- Martelli, A.; Flori, L.; Gorica, E.; Piragine, E.; Saviano, A.; Annunziata, G.; Di Minno, M.N.D.; Ciampaglia, R.; Calcaterra, I.; Maione, F.; et al. Vascular Effects of the Polyphenolic Nutraceutical Supplement Taurisolo®: Focus on the Protection of the Endothelial Function. Nutrients 2021, 13, 1540. [Google Scholar] [CrossRef] [PubMed]
- Ministrini, S.; Puspitasari, Y.M.; Beer, G.; Liberale, L.; Montecucco, F.; Camici, G.G. Sirtuin 1 in Endothelial Dysfunction and Cardiovascular Aging. Front. Physiol. 2021, 12, 733696. [Google Scholar] [CrossRef]
- Singh, C.K.; Chhabra, G.; Ndiaye, M.A.; Garcia-Peterson, L.M.; Mack, N.J.; Ahmad, N. The Role of Sirtuins in Antioxidant and Redox Signaling. Antioxid. Redox Signal. 2018, 28, 643–661. [Google Scholar] [CrossRef]
- Yang, Y.; Liu, Y.; Wang, Y.; Chao, Y.; Zhang, J.; Jia, Y.; Tie, J.; Hu, D. Regulation of SIRT1 and Its Roles in Inflammation. Front. Immunol. 2022, 13, 831168. [Google Scholar] [CrossRef]
- Breitenstein, A.; Wyss, C.A.; Spescha, R.D.; Franzeck, F.C.; Hof, D.; Riwanto, M.; Hasun, M.; Akhmedov, A.; von Eckardstein, A.; Maier, W.; et al. Peripheral Blood Monocyte Sirt1 Expression Is Reduced in Patients with Coronary Artery Disease. PLoS ONE 2013, 8, e53106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hu, Y.; Wang, L.; Chen, S.; Liu, X.; Li, H.; Lu, X.; Yang, X.; Huang, J.; Gu, D. Association between the SIRT1 MRNA Expression and Acute Coronary Syndrome. J. Atheroscler. Thromb. 2015, 22, 165–182. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kalstad, A.A.; Myhre, P.L.; Laake, K.; Opstad, T.B.; Tveit, A.; Solheim, S.; Arnesen, H.; Seljeflot, I. Biomarkers of Ageing and Cardiac Remodeling Are Associated with Atrial Fibrillation. Scand. Cardiovasc. J. 2021, 55, 213–219. [Google Scholar] [CrossRef] [PubMed]
- Cao, D.; Wang, M.; Qiu, X.; Liu, D.; Jiang, H.; Yang, N.; Xu, R.-M. Structural Basis for Allosteric, Substrate-Dependent Stimulation of SIRT1 Activity by Resveratrol. Genes Dev. 2015, 29, 1316–1325. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ma, S.; Feng, J.; Zhang, R.; Chen, J.; Han, D.; Li, X.; Yang, B.; Li, X.; Fan, M.; Li, C.; et al. SIRT1 Activation by Resveratrol Alleviates Cardiac Dysfunction via Mitochondrial Regulation in Diabetic Cardiomyopathy Mice. Oxidative Med. Cell. Longev. 2017, 2017, e4602715. [Google Scholar] [CrossRef] [Green Version]
- Ma, X.; Sun, Z.; Han, X.; Li, S.; Jiang, X.; Chen, S.; Zhang, J.; Lu, H. Neuroprotective Effect of Resveratrol via Activation of Sirt1 Signaling in a Rat Model of Combined Diabetes and Alzheimer’s Disease. Front. Neurosci. 2020, 13, 1400. [Google Scholar] [CrossRef] [Green Version]
- Cong, L.; Lei, M.-Y.; Liu, Z.-Q.; Liu, Z.-F.; Ma, Z.; Liu, K.; Li, J.; Deng, Y.; Liu, W.; Xu, B. Resveratrol Attenuates Manganese-Induced Oxidative Stress and Neuroinflammation through SIRT1 Signaling in Mice. Food Chem. Toxicol. 2021, 153, 112283. [Google Scholar] [CrossRef]
- Walle, T. Bioavailability of Resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215, 9–15. [Google Scholar] [CrossRef]
- Wenzel, E.; Somoza, V. Metabolism and Bioavailability of Trans-Resveratrol. Mol. Nutr. Food Res. 2005, 49, 472–481. [Google Scholar] [CrossRef]
- de Vries, K.; Strydom, M.; Steenkamp, V. A Brief Updated Review of Advances to Enhance Resveratrol’s Bioavailability. Molecules 2021, 26, 4367. [Google Scholar] [CrossRef]
- Scisciola, L.; Sarno, F.; Carafa, V.; Cosconati, S.; Di Maro, S.; Ciuffreda, L.; De Angelis, A.; Stiuso, P.; Feoli, A.; Sbardella, G.; et al. Two Novel SIRT1 Activators, SCIC2 and SCIC2.1, Enhance SIRT1-Mediated Effects in Stress Response and Senescence. Epigenetics 2020, 15, 664–683. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Flori, L.; Petrarolo, G.; Brogi, S.; La Motta, C.; Testai, L.; Calderone, V. Identification of Novel SIRT1 Activators Endowed with Cardioprotective Profile. Eur. J. Pharm. Sci. 2021, 165, 105930. [Google Scholar] [CrossRef] [PubMed]
- An, Y.; Meng, C.; Chen, Q.; Gao, J. Discovery of Small Molecule Sirt1 Activator Using High-Throughput Virtual Screening, Molecular Dynamics Simulation, Molecular Mechanics Generalized Born/Surface Area (MM/GBSA) Calculation, and Biological Evaluation. Med. Chem. Res. 2020, 29, 255–261. [Google Scholar] [CrossRef]
- Dai, H.; Sinclair, D.A.; Ellis, J.L.; Steegborn, C. Sirtuin Activators and Inhibitors: Promises, Achievements, and Challenges. Pharmacol. Ther. 2018, 188, 140–154. [Google Scholar] [CrossRef] [PubMed]
- Hoffmann, E.; Wald, J.; Lavu, S.; Roberts, J.; Beaumont, C.; Haddad, J.; Elliott, P.; Westphal, C.; Jacobson, E. Pharmacokinetics and Tolerability of SRT2104, a First-in-Class Small Molecule Activator of SIRT1, after Single and Repeated Oral Administration in Man. Br. J. Clin. Pharmacol. 2013, 75, 186–196. [Google Scholar] [CrossRef] [Green Version]
- Sands, B.E.; Joshi, S.; Haddad, J.; Freudenberg, J.M.; Oommen, D.E.; Hoffmann, E.; McCallum, S.W.; Jacobson, E. Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis. Inflamm. Bowel Dis. 2016, 22, 607–614. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ciccone, L.; Petrarolo, G.; Barsuglia, F.; Fruchart-Gaillard, C.; Cassar Lajeunesse, E.; Adewumi, A.T.; Soliman, M.E.S.; La Motta, C.; Orlandini, E.; Nencetti, S. Nature-Inspired O-Benzyl Oxime-Based Derivatives as New Dual-Acting Agents Targeting Aldose Reductase and Oxidative Stress. Biomolecules 2022, 12, 448. [Google Scholar] [CrossRef]
- Ciccone, L.; Nencetti, S.; Tonali, N.; Fruchart-Gaillard, C.; Shepard, W.; Nuti, E.; Camodeca, C.; Rossello, A.; Orlandini, E. Monoaryl Derivatives as Transthyretin Fibril Formation Inhibitors: Design, Synthesis, Biological Evaluation and Structural Analysis. Bioorg. Med. Chem. 2020, 28, 115673. [Google Scholar] [CrossRef] [PubMed]
- Bononi, G.; Citi, V.; Lapillo, M.; Martelli, A.; Poli, G.; Tuccinardi, T.; Granchi, C.; Testai, L.; Calderone, V.; Minutolo, F. Sirtuin 1-Activating Compounds: Discovery of a Class of Thiazole-Based Derivatives. Molecules 2022, 27, 6535. [Google Scholar] [CrossRef] [PubMed]
- Pan, W.; Yu, H.; Huang, S.; Zhu, P. Resveratrol Protects against TNF-α-Induced Injury in Human Umbilical Endothelial Cells through Promoting Sirtuin-1-Induced Repression of NF-KB and P38 MAPK. PLoS ONE 2016, 11, e0147034. [Google Scholar] [CrossRef] [Green Version]
- Salminen, A.; Kaarniranta, K.; Kauppinen, A. Crosstalk between Oxidative Stress and SIRT1: Impact on the Aging Process. Int. J. Mol. Sci. 2013, 14, 3834–3859. [Google Scholar] [CrossRef] [Green Version]
- Juhasz, B.; Mukherjee, S.; Das, D.K. Hormetic Response of Resveratrol against Cardioprotection. Exp. Clin. Cardiol. 2010, 15, e134–e138. [Google Scholar] [PubMed]
- Jodynis-Liebert, J.; Kujawska, M. Biphasic Dose-Response Induced by Phytochemicals: Experimental Evidence. J. Clin. Med. 2020, 9, 718. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lou, Z.; Li, X.; Zhao, X.; Du, K.; Li, X.; Wang, B. Resveratrol Attenuates Hydrogen Peroxide-induced Apoptosis, Reactive Oxygen Species Generation, and PSGL-1 and VWF Activation in Human Umbilical Vein Endothelial Cells, Potentially via MAPK Signalling Pathways. Mol. Med. Rep. 2018, 17, 2479–2487. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, L.; Gu, L.; Zhu, D.; Huang, X. Resveratrol Attenuates Hydrogen Peroxide-Induced Apoptosis in Human Umbilical Vein Endothelial Cells. Eur. Rev. 2013, 17, 88–94. [Google Scholar]
- Tantawy, A.H.; Meng, X.-G.; Marzouk, A.A.; Fouad, A.; Abdelazeem, A.H.; Youssif, B.G.M.; Jiang, H.; Wang, M.-Q. Structure-Based Design, Synthesis, and Biological Evaluation of Novel Piperine–Resveratrol Hybrids as Antiproliferative Agents Targeting SIRT-2. RSC Adv. 2021, 11, 25738–25751. [Google Scholar] [CrossRef]
- Yu, H.; Pan, W.; Huang, H.; Chen, J.; Sun, B.; Yang, L.; Zhu, P. Screening Analysis of Sirtuins Family Expression on Anti-Inflammation of Resveratrol in Endothelial Cells. Med. Sci. Monit. 2019, 25, 4137–4148. [Google Scholar] [CrossRef] [PubMed]
- Guo, Y.; Xu, A.; Wang, Y. SIRT1 in Endothelial Cells as a Novel Target for the Prevention of Early Vascular Aging. J. Cardiovasc. Pharmacol. 2016, 67, 465–473. [Google Scholar] [CrossRef]
- Man, A.W.C.; Li, H.; Xia, N. The Role of Sirtuin1 in Regulating Endothelial Function, Arterial Remodeling and Vascular Aging. Front. Physiol. 2019, 10, 1173. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Busch, F.; Mobasheri, A.; Shayan, P.; Stahlmann, R.; Shakibaei, M. Sirt-1 Is Required for the Inhibition of Apoptosis and Inflammatory Responses in Human Tenocytes. J. Biol. Chem. 2012, 287, 25770–25781. [Google Scholar] [CrossRef] [PubMed]
- Buhrmann, C.; Busch, F.; Shayan, P.; Shakibaei, M. Sirtuin-1 (SIRT1) Is Required for Promoting Chondrogenic Differentiation of Mesenchymal Stem Cells. J. Biol. Chem. 2014, 289, 22048–22062. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, X.; Liu, Q.; Wang, M.; Liang, M.; Yang, X.; Xu, X.; Zou, H.; Qiu, J. Activation of Sirt1 by Resveratrol Inhibits TNF-α Induced Inflammation in Fibroblasts. PLoS ONE 2011, 6, e27081. [Google Scholar] [CrossRef] [PubMed]
- Buhrmann, C.; Shayan, P.; Popper, B.; Goel, A.; Shakibaei, M. Sirt1 Is Required for Resveratrol-Mediated Chemopreventive Effects in Colorectal Cancer Cells. Nutrients 2016, 8, 145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nencetti, S.; La Motta, C.; Rossello, A.; Sartini, S.; Nuti, E.; Ciccone, L.; Orlandini, E. N-(Aroyl)-N-(Arylmethyloxy)-α-Alanines: Selective Inhibitors of Aldose Reductase. Bioorg. Med. Chem. 2017, 25, 3068–3076. [Google Scholar] [CrossRef] [PubMed]
- Ciccone, L.; Nencetti, S.; Rossello, A.; Stura, E.A.; Orlandini, E. Synthesis and Structural Analysis of Halogen Substituted Fibril Formation Inhibitors of Human Transthyretin (TTR). J. Enzym. Inhib. Med. Chem. 2016, 31, 40–51. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jorgensen, W.L.; Maxwell, D.S.; Tirado-Rives, J. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids. J. Am. Chem. Soc. 1996, 118, 11225–11236. [Google Scholar] [CrossRef]
- Brogi, S.; Brindisi, M.; Butini, S.; Kshirsagar, G.U.; Maramai, S.; Chemi, G.; Gemma, S.; Campiani, G.; Novellino, E.; Fiorenzani, P.; et al. (S)-2-Amino-3-(5-Methyl-3-Hydroxyisoxazol-4-Yl)Propanoic Acid (AMPA) and Kainate Receptor Ligands: Further Exploration of Bioisosteric Replacements and Structural and Biological Investigation. J. Med. Chem. 2018, 61, 2124–2130. [Google Scholar] [CrossRef] [PubMed]
- Brogi, S.; Fiorillo, A.; Chemi, G.; Butini, S.; Lalle, M.; Ilari, A.; Gemma, S.; Campiani, G. Structural Characterization of Giardia Duodenalis Thioredoxin Reductase (GTrxR) and Computational Analysis of Its Interaction with NBDHEX. Eur. J. Med. Chem. 2017, 135, 479–490. [Google Scholar] [CrossRef] [PubMed]
- Lagorce, D.; Sperandio, O.; Baell, J.B.; Miteva, M.A.; Villoutreix, B.O. FAF-Drugs3: A Web Server for Compound Property Calculation and Chemical Library Design. Nucleic Acids Res. 2015, 43, W200–W207. [Google Scholar] [CrossRef] [PubMed]
- Sirous, H.; Chemi, G.; Campiani, G.; Brogi, S. An Integrated in Silico Screening Strategy for Identifying Promising Disruptors of P53-MDM2 Interaction. Comput. Biol. Chem. 2019, 83, 107105. [Google Scholar] [CrossRef] [PubMed]
- Kao, C.-L.; Chen, L.-K.; Chang, Y.-L.; Yung, M.-C.; Hsu, C.-C.; Chen, Y.-C.; Lo, W.-L.; Chen, S.-J.; Ku, H.-H.; Hwang, S.-J. Resveratrol Protects Human Endothelium from H2O2-Induced Oxidative Stress and Senescence via SirT1 Activation. J. Atheroscler. Thromb. 2010, 17, 970–979. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shimazaki, T.; Noro, N.; Hagikura, K.; Matsumoto, T.; Yoshida-Noro, C. Quantitative Analysis of Factors Regulating Angiogenesis for Stem Cell Therapy. Biology 2021, 10, 1212. [Google Scholar] [CrossRef] [PubMed]
Compound | R | R1 | R2 | R3 | R4 |
---|---|---|---|---|---|
1a | 2-OH | OH | H | H | H |
1b | 2-OH | H | OH | H | H |
1c | 2-OH | H | H | OH | H |
1d | 2-OH | H | OH | H | OH |
1e | 2-OH | OH | H | OH | H |
2a | 3-OH | OH | H | H | H |
2b | 3-OH | H | OH | H | H |
2c | 3-OH | H | H | OH | H |
2d | 3-OH | H | OH | H | OH |
2e | 3-OH | OH | H | OH | H |
3b | 4-OH | H | OH | H | H |
3d | 4-OH | H | OH | H | OH |
3e | 4-OH | OH | H | OH | H |
4a | 2-OCH3 | H | OH | H | OH |
4b | 2-OCH3 | OH | OH | OH | H |
4c | 2-OCH3 | H | OH | OH | H |
4d | 2-OCH3 | OH | H | H | OH |
4e | 2-OCH3 | OH | H | OH | H |
5a | 3-OCH3 | H | OH | H | OH |
5b | 3-OCH3 | OH | OH | OH | H |
5c | 3-OCH3 | H | OH | OH | H |
5d | 3-OCH3 | OH | H | H | OH |
5e | 3-OCH3 | OH | H | OH | H |
6a | 4-OCH3 | H | OH | H | OH |
6b | 4-OCH3 | OH | OH | OH | H |
6c | 4-OCH3 | H | OH | OH | H |
6d | 4-OCH3 | OH | H | H | OH |
6e | 4-OCH3 | OH | H | OH | H |
7 | 2-Cl | H | OH | H | OH |
8 | 3-Cl | H | OH | H | OH |
9 | 4-Cl | H | OH | H | OH |
Cpd | GlideScore (kcal/mol) | ΔGbind (kcal/mol) | SASA a | QPlogP b | QPlogS c | QPPCaco d | QPPMDCK e | QPlogHERG f | %HOA g |
---|---|---|---|---|---|---|---|---|---|
1d | #site1 −7.34 #site2 −7.38 #site3 −7.26 | #site1 −89.2 #site2 −69.1 #site3 −82.6 | 544 | 1.49 | −2.88 | 276 | 131 | −5.86 | 80 |
2d | #site1 −8.21 #site2 −7.59 #site3 −7.42 | #site1 −89.7 #site2 −75.2 #site3 −83.1 | 565 | 1.42 | −2.97 | 194 | 129 | −5.94 | 78 |
3b | #site1 −7.86 #site2 −7.55 #site3 −7.29 | #site1 −90.2 #site2 −76.6 #site3 −82.8 | 532 | 2.27 | −3.21 | 622 | 397 | −6.07 | 89 |
3d | #site1 −8.16 #site2 −7.68 #site3 −7.27 | #site1 −89.4 #site2 −74.5 #site3 −81.9 | 545 | 1.40 | −2.95 | 198 | 126 | −5.95 | 81 |
8 | #site1 −8.26 #site2 −7.22 #site3 −7.53 | #site1 −90.6 #site2 −79.3 #site3 −83.7 | 556 | 2.73 | −3.92 | 621 | 729 | −5.99 | 94 |
9 | #site1 −8.59 #site2 −7.74 #site3 −7.29 | #site1 −91.4 #site2 −77.8 #site3 −82.1 | 557 | 2.69 | −3.87 | 616 | 724 | −5.98 | 95 |
Rsv h | #site1 −7.12 #site2 −7.16 #site3 −7.21 | #site1 −89.2 #site2 −64.7 #site3 −81.4 | 482 | 2.00 | −2.81 | 279 | 123 | −5.33 | 71 |
Compound | Concentration | SIRT1 Activity % |
---|---|---|
Resveratrol | 100 µM | 100.0 ± 2.7 |
Sirtinol | 10 µM | −6.2 ± 4.1 |
1d | 100 µM | 1.1 ± 6.6 |
2d | 100 µM | 19.4 ± 3.4 |
3b | 100 µM | 23.0 ± 5.2 |
3d | 100 µM | 62.8 ± 5.6 |
8 | 100 µM | 4.7 ± 8.5 |
9 | 100 µM | 27.3 ± 5.2 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ciccone, L.; Piragine, E.; Brogi, S.; Camodeca, C.; Fucci, R.; Calderone, V.; Nencetti, S.; Martelli, A.; Orlandini, E. Resveratrol-like Compounds as SIRT1 Activators. Int. J. Mol. Sci. 2022, 23, 15105. https://doi.org/10.3390/ijms232315105
Ciccone L, Piragine E, Brogi S, Camodeca C, Fucci R, Calderone V, Nencetti S, Martelli A, Orlandini E. Resveratrol-like Compounds as SIRT1 Activators. International Journal of Molecular Sciences. 2022; 23(23):15105. https://doi.org/10.3390/ijms232315105
Chicago/Turabian StyleCiccone, Lidia, Eugenia Piragine, Simone Brogi, Caterina Camodeca, Raffaele Fucci, Vincenzo Calderone, Susanna Nencetti, Alma Martelli, and Elisabetta Orlandini. 2022. "Resveratrol-like Compounds as SIRT1 Activators" International Journal of Molecular Sciences 23, no. 23: 15105. https://doi.org/10.3390/ijms232315105